Carolina Zin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carolina Zin has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Débora Tavares de Resendee Silva
Graduate Program in Biomedical Sciences, Federal University of Fronteira Sul (UFFS), Chapecó, Brazil
2 shared publications - Josiano Guilherme Puhle
Universidade do Oeste de Santa Catarina (UNOESC)
2 shared publications - Matheus Ribeiro Bizuti
Universidade Federal da Fronteira Sul
2 shared publications - Natan Rodrigues de Oliveira
Department of Medicine, Federal University of Fronteira Sul, Chapecó, Brazil
2 shared publications - Ana Carolina Gonçalves Zietz
Universidade Federal da Fronteira Sul
1 shared publication - Angela Makeli Kososki Dalagnol
Graduate Program in Biomedical Sciences, Federal University of Fronteira Sul (UFFS), Chapecó, Brazil
1 shared publication
Latest Publications
- 25 March 2025
- Published by Springer Nature in Sport Sciences for Health
- Vol. 21 (3) , 1601-1611
Physical exercise as a modulator of ectonucleotidases activity in lymphocytes and cytokine levels in individuals on hemodialysis
- 25 March 2025
- Published by Springer Nature in Sport Sciences for Health
- Vol. 21 (3) , 1601-1611
Physical exercise as a modulator of ectonucleotidases activity in lymphocytes and cytokine levels in individuals on hemodialysis
- 27 June 2023
- Published by Springer Nature in Purinergic Signalling
- Vol. 20 (3) , 213-222
Physical exercise as a modulator of the purinergic system in the control of sarcopenia in individuals with chronic kidney disease on hemodialysis
The word sarcopenia derives from the Greek terms “sarx” for meat and “penia” for loss, thus being used to define reductions in muscle mass, muscle strength, and lower physical performance that compromise, mainly, the elderly population. Its high negative impact on patients’ quality of life encourages the production and publication of new studies that seek to find methods to prevent and reverse cases of loss of muscle mass and strength. Furthermore, the high prevalence of sarcopenia in patients with chronic kidney disease (CKD) is closely related to its pathophysiology, which consists of a state of increased protein catabolism and decreased muscle tissue synthesis. Also considering the inflammatory nature of CKD and sarcopenia, the purinergic system has been an important target of studies, which seek to relate it to the two previous conditions. This system achieves anti-inflammatory action by inhibiting, through adenosine, pro-inflammatory factors such as interleukin-12 (IL-12), tumor necrosis factor alpha (TNF-α), and nitric oxide (NO), as well as by releasing anti-inflammatory substances such as interleukin-10 (IL-10). Simultaneously, the purinergic system presents pro-inflammatory activity, signaled by adenosine triphosphate (ATP), which occurs through the activation of T cells and the release of pro-inflammatory factors such as those mentioned above. Therefore, the ability of this system to act on inflammatory processes can promote positive and negative changes in the clinical aspect of patients with CKD and/or sarcopenia. Furthermore, it appears that there is a correlation between the practice of repeated physical exercise with the clinical improvement and in the quality of life of these patients, presenting a decrease in the levels of C-reactive protein (CRP), NTPDase, and the pro-inflammatory cytokine IL-6, such as increases in IL-10 resulting from modulation of the purinergic system. In this way, the present article seeks to evaluate the effect of physical exercise as a modulator of the purinergic system in the control of sarcopenia in patients with CKD on hemodialysis, in order to trace a relationship that can bring benefits both for biological markers and for quality of life of these patients.
- 27 June 2023
- Published by Springer Nature in Purinergic Signalling
- Vol. 20 (3) , 213-222
Physical exercise as a modulator of the purinergic system in the control of sarcopenia in individuals with chronic kidney disease on hemodialysis
The word sarcopenia derives from the Greek terms “sarx” for meat and “penia” for loss, thus being used to define reductions in muscle mass, muscle strength, and lower physical performance that compromise, mainly, the elderly population. Its high negative impact on patients’ quality of life encourages the production and publication of new studies that seek to find methods to prevent and reverse cases of loss of muscle mass and strength. Furthermore, the high prevalence of sarcopenia in patients with chronic kidney disease (CKD) is closely related to its pathophysiology, which consists of a state of increased protein catabolism and decreased muscle tissue synthesis. Also considering the inflammatory nature of CKD and sarcopenia, the purinergic system has been an important target of studies, which seek to relate it to the two previous conditions. This system achieves anti-inflammatory action by inhibiting, through adenosine, pro-inflammatory factors such as interleukin-12 (IL-12), tumor necrosis factor alpha (TNF-α), and nitric oxide (NO), as well as by releasing anti-inflammatory substances such as interleukin-10 (IL-10). Simultaneously, the purinergic system presents pro-inflammatory activity, signaled by adenosine triphosphate (ATP), which occurs through the activation of T cells and the release of pro-inflammatory factors such as those mentioned above. Therefore, the ability of this system to act on inflammatory processes can promote positive and negative changes in the clinical aspect of patients with CKD and/or sarcopenia. Furthermore, it appears that there is a correlation between the practice of repeated physical exercise with the clinical improvement and in the quality of life of these patients, presenting a decrease in the levels of C-reactive protein (CRP), NTPDase, and the pro-inflammatory cytokine IL-6, such as increases in IL-10 resulting from modulation of the purinergic system. In this way, the present article seeks to evaluate the effect of physical exercise as a modulator of the purinergic system in the control of sarcopenia in patients with CKD on hemodialysis, in order to trace a relationship that can bring benefits both for biological markers and for quality of life of these patients.